KIGALI, Rwanda, July 20, 2026
Akagera Medicines, Inc. has announced positive first-in-human Phase 1 results for AKG-100, its investigational long-acting intravenous (IV) therapeutic designed to transform the treatment of drug-resistant tuberculosis (DR-TB). The encouraging findings from the single-ascending-dose (SAD) portion of the clinical study demonstrated favorable safety, strong tolerability, and pharmacokinetic properties consistent with long-acting dosing, supporting the possibility of administering treatment every few weeks or even months rather than daily. The study also delivered promising early bactericidal activity, reinforcing the therapeutic potential of AKG-100 to address one of the world’s most persistent infectious diseases. Following these successful results, the company has initiated the multiple-ascending-dose (MAD) phase of the ongoing Phase 1 program, marking another significant milestone in the development of next-generation therapies for multidrug-resistant tuberculosis.
Phase 1 Study Demonstrates Strong Safety and Long-Acting Potential
The single-ascending-dose Phase 1 study evaluated AKG-100 in 40 healthy volunteers together with 15 patients diagnosed with pulmonary tuberculosis participating in a 14-day Early Bactericidal Activity (EBA) cohort. Across all tested dose levels, including the highest 850 mg intravenous dose, the investigational therapy demonstrated a favorable safety profile, with no treatment discontinuations due to adverse events and most reported events classified as mild and self-limiting. Pharmacokinetic analyses revealed that drug concentrations remained above the target therapeutic threshold for at least 14 days following a single administration, while predictive modeling indicated sustained exposure extending beyond 28 days. These findings suggest that AKG-100 may ultimately enable infrequent dosing schedules, representing a major advancement over current tuberculosis regimens that typically require daily oral therapy for six months or longer, often leading to poor patient adherence and treatment failure.
Promising Early Bactericidal Activity Supports Continued Development
In addition to the positive safety findings, investigators reported encouraging evidence of early antibacterial activity in patients with pulmonary tuberculosis. A model-based exploratory analysis indicated that a single dose of AKG-100 produced an estimated 3.7 log10 reduction in bacterial burden by Day 14, corresponding to approximately 99.98% bacterial killing. The study also demonstrated a substantial increase in time to culture positivity, reflecting prolonged suppression of bacterial growth following treatment. Importantly, AKG-100 acts through a mechanism independent of rifampicin and isoniazid, the cornerstone antibiotics used in first-line tuberculosis treatment, while laboratory testing has shown that the investigational therapy retains activity against multidrug-resistant tuberculosis strains. Although these findings remain preliminary and require confirmation in larger studies, they compare favorably with historical early bactericidal activity benchmarks and provide strong scientific justification for advancing into the ongoing multiple-ascending-dose clinical evaluation.
Advertisement
Novel Lipid Nanoparticle Platform Targets Global TB Challenge
AKG-100 is the lead therapeutic candidate developed using Akagera Medicines’ proprietary lipid nanoparticle delivery platform, designed to provide long-lasting drug exposure while reducing treatment burden for patients living with tuberculosis. The innovative technology aims to overcome several longstanding challenges associated with multidrug-resistant tuberculosis, including poor adherence, prolonged treatment duration, and increasing antimicrobial resistance. Beyond tuberculosis, the company’s research pipeline also includes messenger RNA and lipid nanoparticle therapeutics and vaccines targeting RSV, HIV, malaria, Lassa fever, nontuberculous mycobacterial disease, seasonal influenza, avian influenza, and next-generation mumps vaccines. As tuberculosis continues to claim more than one million lives annually, the successful clinical advancement of AKG-100 could represent an important breakthrough in global infectious disease treatment by delivering safer, more effective, and significantly longer-acting therapy capable of improving patient compliance and clinical outcomes worldwide.
Source: Akagera Medicines Press release
